GlassScriptPhysician profile
Thomas Jason Martin
NPI 1245410653
$4,939.75
in general payments reported to CMS, 2019-2025
12 companies · $4,585 in 2025
The $4,585 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.61 · 2020: $62.63 · 2021: $40.51 · 2022: $27.78 · 2023: $52.47 · 2024: $124 · 2025: $4,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,041 · Food and Beverage: $361 · Travel and Lodging: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,040.67 |
| Food and Beverage | $360.75 |
| Travel and Lodging | $359.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,376.79 | 2025 | |
| Glaxosmithkline, LLC. | $169.01 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $160.07 | 2019-2025 | Tezspire |
| Insmed, INC. | $49.89 | 2024-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $35.72 | 2019 | |
| Pfizer INC. | $30.68 | 2024 | |
| Genzyme Corporation | $27.23 | 2025 | |
| Mylan Specialty L.P. | $26.72 | 2020 | |
| Shionogi INC | $19.73 | 2023 | Fetroja |
| Merck Sharp & Dohme LLC | $17.44 | 2023 | |
| Ambu INC. | $14.36 | 2021 | |
| Inogen, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.